Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 13%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc. is positioned for a positive financial outlook, with expectations of sustaining mid-teens revenue growth over the next few years and potential acceleration into the high-teens by 2026, largely driven by new product launches and decreasing market headwinds, particularly in China. The company is anticipated to enhance both its gross and operating margins, alongside delivering earnings per share (EPS) growth that exceeds revenue growth. Additionally, the potential for rapid growth in its neurovascular franchise and increasing adoption within vascular treatments highlights Penumbra's capacity to outperform competitors and solidifies its status as a market leader with profitable operations.

Bears say

Penumbra Inc faces significant challenges that could adversely affect its financial performance, including increased competition in the mechanical thrombectomy sector and potential setbacks in new product approvals and market integration. The company's dependence on the U.S. market exposes it to risks related to changes in reimbursement practices, which could further dampen growth prospects. Additionally, slower customer acquisition and procedural dynamics, along with regulatory delays, heighten the risk of underperformance against both internal expectations and broader market conditions.

Penumbra (PEN) has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 16 analysts, Penumbra (PEN) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $359.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $359.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.